This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
PCI Biotech Holding ASA
Q22024
8/28/2024
Ronny Skuggerahl
CEO, PCI Biotech
Hi, and welcome to PCI Biotech's first half-year 2024 presentation. My name is Ronny Skuggerahl. With me today is Morten Lur, who is responsible for business development and project manager for our bioprocess project. Let's take a look at our important notice and disclaimer. Agendaen i dag, først operational review, fokus på bioprosessprosjektet vårt, så litt rundt finans og outlook, og så til slutt en Q&A session, og jeg oppfordrer dere allerede nå til å sende inn skriftlige spørsmål via webcast-konsolen, sånn at vi er sikre på at vi har dem i hendet før vi kommer så langt. Da I give the floor to Morten.
Morten Lur
Head of Business Development & Project Manager, Bioprocess Project
Good morning. Gen therapies are biological drugs with life-threatening potential, where there have been major breakthroughs in the treatment of both blood
Disclaimer